Real Estate, Mortgage News

Real Estate News and Press Release Distribution Services
Submit Press Release | Submit RSS Feed | About US | Contact Us

Home | Real Estate News | Mortgage Rates
Unlimited Press Release Distribution
Press release distribution service


News Media
CNN Money
Costar Group
Inman News


Los Angeles Times


National Real Estate Investor
Mortgage News Daily
New York Times
Realtor Magazine
RISMedia
Wall Street Journal
Yahoo Finance
Zawya
RSS News Feed
Get your news feed listed here as other news media shown below! Submit RSS News Feed

Mercury News
New York Post

Real Estate News Releases

LegalView Creates New Informational Practice Areas for Unsafe Drugs Risperdal and Dostinex

(EMAILWIRE.COM, September 17, 2007 ) DENVER, CO - LegalView.com, your complete source for everything legal on the web, would like to announce that readers can now find a wealth of important information regarding two prescription drugs that have been shown to be potentially hazardous to patients, Risperdal and Dostinex. Each of these drugs have been linked to potentially life-threatening side-effects, of which all patients should be aware. By consulting LegalView’s Risperdal and Dostinex Information portals, at risperdal.legalview.com and dostinex.legalview.com respectively, readers can gain valuable information about the potential negative side effects of these two drugs.Risperdal, also known by its generic name Risperidone, is a prescription medication for the treatment of schizophrenia, a severe mental disorder that can cause delusions and hallucinations. It is also used for the short-term treatment of mania associated with bipolar disorder. Risperdal is in a class of medications called atypical anti-psychotics, also known as second generation anti-psychotics, which differ from other anti-psychotics in that they work by muting the impact of dopamine and serotonin, two of the brain's key chemical messengers. Some concern has arisen over Risperdal, as it appears the drug may be responsible for an increased chance of death in elderly persons. Elderly patients treated with atypical anti-psychotics, such as Risperdal, for dementia had a higher chance for death than patients who did not take the medicine, according to the Food and Drug Administration. Risperdal has also been connected in some patients with the onset of a life-threatening nervous system problem called neuroleptic malignant syndrome (NMS). NMS can cause a high fever, stiff muscles, sweating, a fast or irregular heart beat, change in blood pressure, and confusion. Anyone who has experienced these symptoms should consult their physician as soon as possible. For more information about the drug, or to be put in touch with a Risperdal law firm, consult LegalView’s Risperdal Information portal. Dostinex, also known by the generic name of its active ingredient Cabergoline, is a prescription medication used to treat certain hormone problems involving excess prolactin. The drug is also used to reduce or prevent breast milk production, except after childbirth (postpartum). In addition, this drug may also be used to treat Parkinson's disease in some cases, treat prolactin-producing tumors and to adjust various hormone levels in certain diseases (ovarian diseases). Side effects that should also be reported promptly can include mental or mood changes, fainting, swelling of feet or ankles, breast pain, menstrual changes, vision problems. In addition to these side effects, in two studies published in the New England Journal of Medicine on January 4, 2007, Dostinex was implicated along with pergolide in causing valvular heart disease in some patients. Both drugs are ergot-derived dopamine agonists, although their molecular skeletons are different. As a result of this, the Food and Drug Administration removed pergolide from the U.S. market on March 29, 2007. Dostinex is approved in the U.S. for the treatment of hyperprolactinemic disorders (conditions in which there are elevated levels of prolactin in the blood). Dostinex is not usually prescribed for the treatment of Parkinson’s diseas, however, any patients who have received Dostinex as a treatment for Parkinson's should consult with their physician as to whether the dosage of the drug they received may contribute to valvular heart disease. For more information, or to contact an experienced Dostinex attorney readers should visit the Dostinex information portal.The Dostinex and Risperdal portals are just part of LegalView's collection of free, comprehensive information on the legal issues important to Americans. Readers may also be interested in news, statistics, research and legal information regarding a brain injury attorney, a mesothelioma lawyer, a birth injury law firm or a defective airbag attorney. On all of these sites and others in LegalView's family of free informational Web portals, visitors can find original articles explaining the issue in plain language; links to legal resources; glossaries of medical terms, where appropriate; government warnings and releases; and much more. And if you believe you may have a lawsuit on these topics or others, LegalView offers visitors a way to connect with expert attorneys in your area who can evaluate your case for no charge.LegalView.com is a free service to the public, brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of highly respected national law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's distinguished sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.legalview.com.Contact:Peter Kentpress-releases@legalview.com


LegalView
Peter Kent

press-releases@legalview.com


Real Estate News by Sector
  • Appraiser
  • Consumer News
  • Commercial
  • Mortgage News
  • Property Law
  • REIT News
  • Sales, Marketing
  • Technology

  • Real Estate RSS Marketpalce

    Submit RSS news feed on Real Estate.
    Have your feed on real estate news, products or services displayed under this marketpalce and have your feed on a full page updated daily. Click on example below. Add RSS feed Now!

    EmailWire Real Estate News Releases
    News releases on real estate as posted by businesses, organizations and experts.


    Press release service

    ESTATENewswire is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

    For unlimited press release distribution for $99 per month or $999 per year, call (281) 645-4086 or start posting your press releases online at EmailWire.com.
    Copyright 2009 GroupWeb Media LLC

    GroupWeb Media Network
    AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
    | InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
    ESTATENewswire.Com - Newswire and Press Release service of GroupWeb Media LLC